GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LENSAR Inc (NAS:LNSR) » Definitions » ROC (Joel Greenblatt) %

LENSAR (LENSAR) ROC (Joel Greenblatt) % : -59.87% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is LENSAR ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. LENSAR's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -59.87%.

The historical rank and industry rank for LENSAR's ROC (Joel Greenblatt) % or its related term are showing as below:

LNSR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -198.12   Med: -152.03   Max: -65.48
Current: -65.48

During the past 5 years, LENSAR's highest ROC (Joel Greenblatt) % was -65.48%. The lowest was -198.12%. And the median was -152.03%.

LNSR's ROC (Joel Greenblatt) % is ranked worse than
63.76% of 850 companies
in the Medical Devices & Instruments industry
Industry Median: -0.61 vs LNSR: -65.48

LENSAR's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


LENSAR ROC (Joel Greenblatt) % Historical Data

The historical data trend for LENSAR's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LENSAR ROC (Joel Greenblatt) % Chart

LENSAR Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-198.12 -182.78 -152.03 -150.01 -72.03

LENSAR Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -81.36 -102.75 -58.84 -40.49 -59.87

Competitive Comparison of LENSAR's ROC (Joel Greenblatt) %

For the Medical Devices subindustry, LENSAR's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LENSAR's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LENSAR's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where LENSAR's ROC (Joel Greenblatt) % falls into.



LENSAR ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.848 + 17.481 + 2.132) - (5.706 + 1.133 + 3.618)
=13.004

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.001 + 15.689 + 2.367) - (5.716 + 1.383 + 3.974)
=10.984

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of LENSAR for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-11.844/( ( (7.438 + max(13.004, 0)) + (8.138 + max(10.984, 0)) )/ 2 )
=-11.844/( ( 20.442 + 19.122 )/ 2 )
=-11.844/19.782
=-59.87 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LENSAR  (NAS:LNSR) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


LENSAR ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of LENSAR's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


LENSAR (LENSAR) Business Description

Traded in Other Exchanges
N/A
Address
2800 Discovery Drive, Orlando, FL, USA, 32826
LENSAR Inc is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency and reproducibility by providing imaging, simplified procedure planning, efficient design and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The consumable portion of the system consists of a disposable patient interface device, or PID, kit and a procedure license. Each procedure on each system requires the use of a PID kit.
Executives
Gary M Winer director C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Aimee S Weisner director ONE EDWARDS WAY, IRVINE CA 92614
Nr-gri Partners Gp, Llc 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Nr-gri Partners, Lp 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Todd B Hammer director, 10 percent owner NORTH RUN CAPITAL PARTNERS, 867 BOYLSTON ST., 5TH FLOOR, #1361, BOSTON MA 02116
Thomas B Ellis director, 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
North Run Advisors, Llc 10 percent owner 62 WALNUT STREET, WELLESLEY MA 02481
North Run Capital, Lp 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Staab Thomas R Ii officer: Chief Financial Officer C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Kendra Wong officer: Principal Accounting Officer C/O LENSAR, INC., 2800 DISCOVERY DRIVE, SUITE 100, ORLANDO FL 32826
Elizabeth G. O'farrell director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Alan B. Connaughton officer: Chief Operating Officer C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Nicholas T Curtis director, officer: Chief Executive Officer C/O STAAR SURGICAL CO, 1911 WALKER AVE, MONROVIA CA 91016
Pdl Biopharma, Inc. 10 percent owner 59 DAMONTE RANCH PARKWAY, SUITE B-375, RENO NV 89521
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391

LENSAR (LENSAR) Headlines